Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of ONCT will decline by -95.12% over the next 2 Weeks and hit $0.03 by Tuesday, January 14, 2025. In that time frame, ONCT's share price is expected to range between $0.00 and $0.21.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Jan 14, 2025 | 0.00 | 0.13 | 0.30 |
| Jan 13, 2025 | 0.00 | 0.10 | 0.27 |
| Jan 10, 2025 | 0.03 | 0.20 | 0.37 |
| Jan 9, 2025 | 0.03 | 0.22 | 0.39 |
| Jan 8, 2025 | 0.01 | 0.19 | 0.37 |
| Jan 7, 2025 | 0.07 | 0.23 | 0.40 |
| Jan 6, 2025 | 0.04 | 0.21 | 0.37 |
| Jan 3, 2025 | 0.12 | 0.30 | 0.48 |
| Jan 2, 2025 | 0.16 | 0.32 | 0.49 |
| Jan 1, 2025 | 0.13 | 0.29 | 0.46 |
ONCT shares fell -24.12% in Monday, December 2, 2024's trading session, dropping from a previous close of $0.69 to move at $0.53. The stock demonstrated notable intraday movement (see ONCT's key stats for a full breakdown), fluctuating between $0.53 and $0.70, a +32.93% trading range. While recent weeks have seen some volatility, ONCT has managed to secure a 0 no change over the past 2 weeks. The downward price movement was accompanied by remained steady trading volume, with approximately 0 shares changing hands, 0 fewer than the previous session. This amounted to $0.00 in total market activity.
Will ONCT Continue Its Downward Trend?
According to analyst ratings and projections for ONCT, Oncternal Therapeutics, Inc. shares are anticipated to decrease by -77.76%, potentially reaching $0.30 per share by January 14, 2025. Short-term technical indicators for ONCT currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 25 negative trading days within the past 30 sessions. Based on the ONCT stock forecast, now is not the best time to buy ONCT stock because its current trading price is +313.99% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on ONCT covering social and institutional perspectives.
ONCT Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into ONCT's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 18.82% to 28.75%) suggest the stock is in a strong bearish momentum phase. The 50-day RSI, at 34.11%, hints at potential weakness developing in the medium term. Meanwhile, the 100-day RSI, at 39.92%, signals a bearish bias in the long-term trend. Insights into ONCT's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Oncternal Therapeutics, Inc. Monthly Forecast 2024–2025
December 2024
According to our latest forecast models, Oncternal Therapeutics, Inc. (ONCT) is positioned to show a strong performance in December 2024. The price is predicted to move between $0.00 and $4.39, settling at an average of $0.00. This could translate to a -100.00% loss.
January 2025
Based on current market signals, Oncternal Therapeutics, Inc. is projected to trend january 2025. We forecast a trading range from $0.00 to $4.40, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
February 2025
Our predictive algorithms indicate Oncternal Therapeutics, Inc. stock may see a shift in February 2025. The expected range spans $0.00–$4.33, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
March 2025
Analyzing established trends, Oncternal Therapeutics, Inc. looks set to move in March 2025. Projections place the stock between $0.00 and $4.69, averaging around $0.00. This suggests a -100.00% loss from current levels.
April 2025
Market indicators suggest Oncternal Therapeutics, Inc. could experience notable changes during April 2025. Prices could fluctuate within $0.00 to $4.75, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
May 2025
Forecasting for May 2025, models estimate that Oncternal Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $4.18, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
June 2025
According to our latest forecast models, Oncternal Therapeutics, Inc. (ONCT) is positioned to show a strong performance in June 2025. The price is predicted to move between $0.00 and $4.40, settling at an average of $0.00. This could translate to a -100.00% loss.
July 2025
Based on current market signals, Oncternal Therapeutics, Inc. is projected to trend july 2025. We forecast a trading range from $0.00 to $4.29, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
August 2025
Our predictive algorithms indicate Oncternal Therapeutics, Inc. stock may see a shift in August 2025. The expected range spans $0.00–$4.49, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
September 2025
Analyzing established trends, Oncternal Therapeutics, Inc. looks set to move in September 2025. Projections place the stock between $0.00 and $4.78, averaging around $0.00. This suggests a -100.00% loss from current levels.
October 2025
Market indicators suggest Oncternal Therapeutics, Inc. could experience notable changes during October 2025. Prices could fluctuate within $0.00 to $4.36, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
November 2025
Forecasting for November 2025, models estimate that Oncternal Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $4.65, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
December 2025
According to our latest forecast models, Oncternal Therapeutics, Inc. (ONCT) is positioned to show a strong performance in December 2025. The price is predicted to move between $0.00 and $4.13, settling at an average of $0.00. This could translate to a -100.00% loss.
ONCT's history of dividends and stock splits also plays a role in long-term investor confidence.

